Hikma Pharmaceuticals (LON:HIK) Earns “Buy” Rating from Jefferies Financial Group

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “buy” rating reissued by research analysts at Jefferies Financial Group in a note issued to investors on Friday, Digital Look reports. They currently have a GBX 2,025 price objective on the stock. Jefferies Financial Group’s target price points to a potential upside of 25.93% from the company’s previous close.

Several other equities analysts also recently commented on HIK. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a GBX 1,950 price objective on shares of Hikma Pharmaceuticals in a report on Friday, August 7th. Citigroup raised their target price on shares of Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Finally, Berenberg Bank lifted their target price on shares of Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Six analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of GBX 2,085.83.

Hikma Pharmaceuticals Stock Performance

HIK opened at GBX 1,608 on Friday. Hikma Pharmaceuticals has a 12-month low of GBX 1,187 and a 12-month high of GBX 1,865. The business has a 50 day moving average of GBX 1,602.32 and a 200-day moving average of GBX 1,475.50. The company has a quick ratio of 1.27, a current ratio of 1.98 and a debt-to-equity ratio of 77.57. The stock has a market cap of £3.33 billion, a price-to-earnings ratio of 9.14, a PEG ratio of 2.38 and a beta of 0.66.

Insider Buying and Selling

In other Hikma Pharmaceuticals news, insider Tobias Hestler acquired 7,500 shares of the company’s stock in a transaction on Monday, August 10th. The stock was acquired at an average price of GBX 1,648 per share, for a total transaction of £123,600. Corporate insiders own 22.26% of the company’s stock.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.